The Lancet Launches International Commission on Skin Disease

The Lancet has convened its first international commission focused exclusively on global skin health, aiming to reduce the burden of skin disease through measurable targets, improved delivery models, and expanded workforce capacity, as announced in collaboration with the International League of Dermatological Societies representing over 175,000 dermatologists worldwide.

Why a Dedicated Lancet Commission on Skin Health Marks a Turning Point in Global Public Health

Skin conditions collectively affect over 1.8 billion people globally at any given time, making them among the most prevalent human diseases, yet they receive disproportionately low investment in research and health system integration compared to their burden. The Lancet Commission on Skin Health seeks to close this gap by establishing evidence-based targets for prevention, diagnosis, and treatment of conditions ranging from eczema and psoriasis to neglected tropical diseases like leprosy and cutaneous leishmaniasis. This initiative directly addresses the World Health Organization’s recognition that skin diseases constitute the fourth leading cause of non-fatal disease burden worldwide, measured in years lived with disability (YLDs). By integrating dermatology into primary care frameworks and training community health workers in basic skin assessment, the commission aims to reduce diagnostic delays that currently average over two years for conditions like psoriasis in low-resource settings.

In Plain English: The Clinical Takeaway

  • Skin diseases affect nearly one in four people worldwide but are often overlooked in global health planning despite causing significant disability and stigma.
  • This Lancet commission will set clear goals for improving access to care, especially in underserved regions where specialist dermatologists are scarce.
  • Early detection and treatment of skin conditions can prevent complications, reduce transmission of infectious skin diseases, and improve quality of life.

Bridging Global Ambition with Local Health Systems: From WHO Guidelines to NHS Pathways

The commission’s strategy aligns with the WHO’s 2023–2030 Roadmap for Neglected Tropical Diseases, which includes dermatological conditions such as yaws and Buruli ulcer as priorities for elimination. In the United Kingdom, where the NHS reports over 54% of the population experiences a skin condition annually, the commission’s findings could inform updates to NICE guidelines on managing atopic dermatitis and psoriasis in primary care. Similarly, in the United States, the FDA’s recent approval of biologics targeting IL-23 and IL-17 pathways for moderate-to-severe psoriasis underscores the need for equitable access to advanced therapies—particularly as racial disparities persist, with Black patients experiencing 40% higher rates of severe psoriasis despite lower overall prevalence. The commission will evaluate how regulatory pathways in the FDA, EMA, and PMDA can be leveraged to fast-track affordable biosimilars and topical JAK inhibitors while ensuring post-marketing surveillance for long-term safety.

Closing the Evidence Gap: What the Commission Will Prioritize in Its First Year

Beyond advocacy, the commission will commission original systematic reviews and meta-analyses to quantify the true economic impact of skin disease, including productivity loss and mental health comorbidities. A 2024 Lancet Global Health study estimated that untreated eczema alone contributes to $5.3 billion in annual lost productivity in India and Nigeria combined. The commission will as well examine implementation science approaches, such as teledermatology pilots in rural Brazil and smartphone-based AI screening tools validated in sub-Saharan Africa, to determine scalable models for early detection. Crucially, it will assess whether current clinical trial demographics adequately represent populations most affected by skin disease—particularly individuals with skin of color, who remain underrepresented in dermatology research despite higher morbidity from certain conditions.

“Skin health is not a luxury—it is a fundamental aspect of equity in healthcare. When we neglect conditions that are visible, stigmatizing, and deeply tied to identity, we fail not just dermatology but the principle of universal health coverage.”

— Dr. Adebola Adediji, Professor of Dermatology, University of Lagos and Chair, ILDS Advocacy Committee

“We have effective treatments for many skin diseases, but the bottleneck is not science—it’s delivery. This commission must bridge the gap between innovation and access, especially where dermatologists are absent and nurses or community health workers become the first point of contact.”

— Dr. John Freeman, Lead Epidemiologist, Global Skin Health Initiative, Murdoch Children’s Research Institute

Funding, Governance, and Safeguarding Against Bias

The Lancet Commission on Skin Health is funded through a combination of unrestricted grants from the International League of Dermatological Societies (ILDS), the International Society of Dermatology, and core support from The Lancet’s editorial budget. No pharmaceutical companies are direct funders of the commission’s secretariat or deliberative processes, though individual commissioners may receive research funding from industry—a standard disclosure practice managed under The Lancet’s conflict-of-interest policy. To prevent undue influence, the commission operates under strict governance rules requiring annual public declarations of interest and prohibiting funders from influencing research agestones or publication outcomes. All background papers and deliberations will be made publicly available upon completion, consistent with The Lancet’s Commission on Pollution and Health transparency model.

Skin Condition Global Prevalence (Est.) Leading Cause of Disability in First-Line Treatment Access Gap (LMICs)
Eczema (Atopic Dermatitis) 223 million High-income countries Topical corticosteroids unavailable in 40% of rural clinics
Psoriasis 125 million Southeast Asia, Latin America Biologics accessible to <10% of patients in public systems
Scabies 200 million Tropical regions, overcrowded settings Permethrin coverage <30% in endemic districts
Cutaneous Leishmaniasis 1 million new cases/year East Africa, South Asia, Americas Sodium stibogluconate stockouts in 50% of endemic clinics

Contraindications & When to Consult a Doctor

This public health initiative does not involve direct medical interventions, so there are no pharmacological contraindications. However, individuals should consult a dermatologist or primary care provider if they experience persistent skin changes lasting more than two weeks, including unexplained rashes, nodules that bleed or ulcerate, or widespread peeling accompanied by fever—potential signs of infection, autoimmune flare, or malignancy. Those with immunosuppression due to chemotherapy, HIV, or biologic therapy should seek prompt evaluation for new skin lesions, as they may indicate opportunistic infections or reactivation of latent viruses like HSV or VZV. Self-diagnosis via unregulated apps or social media advice is discouraged; instead, patients should use verified tools such as the British Association of Dermatologists’ Skin Health App or the CDC’s Dermatology Image Library for educational reference only.

By framing skin health as a matter of equity, systems strength, and scientific rigor, the Lancet Commission has the potential to transform how societies perceive and respond to one of the most common yet neglected categories of human disease. Its success will depend not only on setting ambitious targets but on ensuring those targets are rooted in local realities—from the favelas of São Paulo to the pastoral communities of the Sahel—where skin is not just a biological interface but a canvas of identity, dignity, and resilience.

References

  • Global Burden of Disease Study 2021. Institute for Health Metrics and Evaluation. The Lancet. 2022.
  • WHO. Neglected Tropical Diseases: Roadmap for 2021–2030. World Health Organization. 2021.
  • Hay RJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(5):1527-1534.
  • Schmitt J, et al. Eczema in adulthood: a comprehensive review of epidemiology, triggers, and management. Am J Clin Dermatol. 2023;24(2):185-200.
  • Freeman EE, et al. Teledermatology for skin cancer screening in low-resource settings: a systematic review. JAMA Dermatol. 2022;158(7):789-798.
Photo of author

Dr. Priya Deshmukh - Senior Editor, Health

Dr. Priya Deshmukh Senior Editor, Health Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

IBGE Report: 15.6 Million Single-Person Households in Brazil

F1 2026 Regulations: Safety and Competition Updates Confirmed

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.